English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

herapy for RA has improved rapidly since the advent f biologics. However, although biologics have a greater ffect compared to that with conventional disease modifying ntirheumatic drugs (DMARDs), the cost of these newer therpies remains extremely high.1 Patients in whom biologics re effective have increased employment opportunities due to educed disease activity, meaning that the cost-effectiveness f the treatment is valid. However, in cases where the adminstration of biologics is not associated with a response, disease ctivity during the period of treatment and the progresion of joint damage place an incalculable burden on both

revista brasileira de reumatologia

A hepcidina‐25 dá uma indicação da eficácia terapêutica do tocilizumab na artrite reumatoide – Relação entre a atividade da doença na artrite reumatoide e a anemia